CytRx (CYTR) Reports Statistically Significant Results from Aldoxorubicin Phase 2b
Tweet Send to a Friend
CytRx Corporation (Nasdaq: CYTR) announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE